DOCSLIB.ORG

BBSRC Business July 2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BBSRC Business July 2008 July BBSRCbusiness 2008 the quarterly magazine of the Biotechnology and Biological Sciences Research Council Contents July 2008 BBSRC The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK’s principal funder of basic and strategic biological research. This covers topics such as: genomics, molecular biology, cell biology and bionanotechnology that provide a basis for new technologies in the healthcare, food safety, plant and livestock breeding, and bio-processing sectors; whole organism biology relevant to our 5 6 12 7 understanding of diet and health, ageing, animal health and welfare, infectious diseases business and immunity, and crop productivity; and biological populations and systems that Chief Executive’s column 2 Diversity 7 Major UK funders publish common support agricultural sustainability, biodiversity Achieving a diverse research community in BBSRC rules for animal research 15 and novel bio-based processes in Bioscience:Biomillions 3 New guidelines published through the National manufacturing. Mission to Brazil 11 Showcasing the economic and social impact Centre for the Replacement, Refinement and We help to ensure that the UK has the high calibre of our research Discussions on sustainable biotechnology, including Reduction of Animals in Research scientists and the research infrastructure to remain biofuels, as part of the UK-Brazil Year of Science Mathematics as a tool to defeat a world leader in the biological sciences. We and Innovation New Research Complex at Harwell 16 encourage knowledge transfer from research into plant and animal diseases 4 A major initiative to bring together the life and BBSRC-sponsored research at the Royal Flying in the face of change 12-13 business and policy applications and we foster physical sciences in one building public dialogue about advances in research and Society Summer Exhibition The dramatic impacts of climate change on aphids their implications. BBSRC And finally…… inside back cover Sheffield spin-out wins additional Raising the media profile of the New tests for farm animal diseases For further information visit: www.bbsrc.ac.uk investment for novel therapeutic biosciences 14 The views expressed in articles in BBSRC proteins 6 How BBSRC supports its researchers in talking with the media business are those of the authors, and do The story of Asterion Ltd and its versatile not necessarily represent the views of the therapeutic platform technology Biotechnology and Biological Sciences 16 Research Council. Data protection If you receive your copy of BBSRC business by post (rather than, for example, through an internal International honour Nobel Peace Prize winners distribution system at your place of work) details of your name and address are held on our mailing list database. If at any time you would like your details Professors Keith Goulding and John Innes Centre scientist to be removed from our database, please contact David Powlson and Dr Andy Whitmore from Professor Caroline Dean OBE FRS has been us and we will do so. Rothamsted Research are three of the elected as a Foreign Associate of the USA’s Intergovernmental Panel on Climate Comments and enquiries National Academy of Sciences for her Change (IPCC) scientists awarded a share excellence in original scientific research. should be addressed to the editor: of the 2007 Nobel Peace Prize. Their This is one of the highest scientific honours Catharine Stott longstanding research to understand soil given in the USA, with only 18 Foreign BBSRC, Polaris House, North Star Avenue, processes such as carbon cycling, was Associates elected worldwide each year. Swindon SN2 1UH recognised with certificates acknowledging Caroline’s lab has worked on the molecular Tel: 01793 414695. Fax: 01793 413382 their significant contributions to the Panel’s and genetic basis of vernalisation and the Email: [email protected] work. The Panel shares the 2007 Nobel way plants are able to time when they flower. Next issue - October 2008 Peace Prize with former US Deputy This world-leading research has influenced President Al Gore. the whole of biology. She is the sole female http://nobelprize.org/nobel_prizes/peace/la UK-based scientist elected this year, and is ureates/2007/ the third scientist from the institute to receive BBSRC is part of the Research Councils the honour. “This is a reflection of the UK partnership. international regard for our top research,” commented Professor Chris Lamb FRS, Andy Whitmore, David Powlson Director of the John Innes Centre. and Keith Goulding. Cover: The surface of a growth hormone shown in intimate contact with residues from two receptors (see page 6). Credit Courtesy of Asterion. BBSRCbusiness BBSRCbusiness Chief Executive‘s column Bioscience : Biomillions showcasing the economic and social The way ahead impact of our research In May, BBSRC held a successful event at HM Treasury called ‘Bioscience: In May, around a hundred invited guests, including Biomillions’, which showcased the contribution of our research to innovation parliamentarians, officials from HM Treasury and other and the UK economy (see opposite). government departments, and leading figures from the bio-business and research communities, joined us to We were delighted that Ian Pearson MP, Minister for recent announcement of a LINK award with the Home Grown celebrate the success of UK bioscience research. Science and Innovation, gave two hours from his crowded Cereals Authority. Through this we will support research at schedule to meet the researchers and discuss their science. the John Innes Centre into substituting mineral oil with I am grateful to all those from the research and business rapeseed oil to reduce the lubricants industry’s carbon footprint. The event, ‘Bioscience:Biomillions’ communities who took part. Everyone is busy; but coming I am confident that examples such as these will increase as highlighted the research outcomes by around 50 leading together like this from time to time is important. However many we expand our collaborative research with industry and the UK scientists. Examples ranged from a new screening times we say that the continuing strength of UK bioscience economic and social impact of our research. technology of carbohydrate-protein interactions, relevant to Speakers at ‘Bioscience:Biomillions’: BBSRC Interim Chief Executive Steve depends on coherent and mutually supportive approaches by Later this year, Professor Nigel Brown moves to the development of novel glycotherapeutics, to environmentally- government, funders, industry and academia, nothing can Visscher; Council member and Senior Vice President of GlaxoSmithKline, University of Edinburgh to become Vice-Principal and Head Professor Jackie Hunter; Ian Pearson MP, Minister of State for Science and substitute for face to face communication. It enables us to take friendly solvents for bio-processing and to commercial forage of the College of Science and Engineering, and Dr Doug Innovation; and BBSRC Chairman Dr Peter Ringrose. stock and ‘see the bigger picture’, and to explore new and turf grasses. Yarrow retires as BBSRC Director of Corporate Science. opportunities for networking and collaborations. Ian Pearson MP, Minister of State for Science and On behalf of BBSRC I wish them both well. Each has As our Chairman, Dr Peter Ringrose, said in his address, innovation, spent two hours touring the displays and contributed enormously to the Council’s success and in a particularly important feature of the major economic and discussing the science. In his address, he emphasised the developing our vision of ever stronger bioscience in the UK. social impacts showcased is that they derive from world importance to UK global competitiveness of researchers Finally I take this opportunity to welcome the new class fundamental science. The researchers whose work we continuing to maximise the economic and social impacts BBSRC Chief Executive, Professor Douglas Kell, who takes highlighted are those who also attend international science of their activities. Professor Jackie Hunter, Senior Vice up his post on 1 October. We all very much look forward to conferences. There need be no conflict between academic President of GlaxoSmithKline and a member of BBSRC working with him as we develop our strategy for 2009-2014. excellence and translating outputs into commercial and other Council described the importance of a strong research base I have been privileged to serve as Interim Chief Executive outcomes. Over the last decade this message has gained in fundamental bioscience to the pharmaceutical and related since September 2007 and wish to covey my thanks to the wider acceptance across the research community. However, business sectors. In his remarks, BBSRC Chairman, Dr Peter many people throughout BBSRC and our wider community there are still those who seem reluctant to recognise it. Ringrose stressed the synergy in promoting scientific who have provided me with excellent support. We must continue to demonstrate the mutual benefits excellence and knowledge transfer, and BBSRC’s commitment to increase its activities to increase the impact that accrue from academics working closely with industry Steve Visscher Dr Stefan Przybrorski, Director of the neural stem cell research spin-out company and other end-users of their research. Interim Chief Executive of the research it funds. ReInnervate Limited (left), talks to Ian Pearson MP, Steve Visscher and Dr Ian This mutuality is easy to see. Last month, the Gibson, MP, a member of the Innovation, Universities
Load more

Recommended publications
  • Annual Scientific Report 2013 on the Cover Structure 3Fof in the Protein Data Bank, Determined by Laponogov, I
    EMBL-European Bioinformatics Institute Annual Scientific Report 2013 On the cover Structure 3fof in the Protein Data Bank, determined by Laponogov, I. et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Structural & Molecular Biology 16, 667-669. © 2014 European Molecular Biology Laboratory This publication was produced by the External Relations team at the European Bioinformatics Institute (EMBL-EBI) A digital version of the brochure can be found at www.ebi.ac.uk/about/brochures For more information about EMBL-EBI please contact: [email protected] Contents Introduction & overview 3 Services 8 Genes, genomes and variation 8 Molecular atlas 12 Proteins and protein families 14 Molecular and cellular structures 18 Chemical biology 20 Molecular systems 22 Cross-domain tools and resources 24 Research 26 Support 32 ELIXIR 36 Facts and figures 38 Funding & resource allocation 38 Growth of core resources 40 Collaborations 42 Our staff in 2013 44 Scientific advisory committees 46 Major database collaborations 50 Publications 52 Organisation of EMBL-EBI leadership 61 2013 EMBL-EBI Annual Scientific Report 1 Foreword Welcome to EMBL-EBI’s 2013 Annual Scientific Report. Here we look back on our major achievements during the year, reflecting on the delivery of our world-class services, research, training, industry collaboration and European coordination of life-science data. The past year has been one full of exciting changes, both scientifically and organisationally. We unveiled a new website that helps users explore our resources more seamlessly, saw the publication of ground-breaking work in data storage and synthetic biology, joined the global alliance for global health, built important new relationships with our partners in industry and celebrated the launch of ELIXIR.
    [Show full text]
  • Download the Main Panel A
    Panel A Main Panel A Chair Professor Stephen Holgate University of Southampton Members Professor Alan Barrett University of Texas Medical Branch Professor Christopher Day Newcastle University Association of Medical Research Mr Simon Denegri Until May 2011 Charities Professor Garret Fitzgerald University of Pennsylvania Until Dec 2011 Professor Jack Gauldie McMaster University Professor Trisha Greenhalgh Queen Mary University of London Dr Russell Hamilton Department of Health Professor Glyn Humphreys University of Oxford Professor Mi Ja Kim University of Illinois Joined Oct 2012 Professor Hugh McKenna University of Ulster Professor Bruce Murphy Université de Montréal Professor Jon Nicholl University of Sheffield Professor Ole Petersen Cardiff University Dr Malcolm Skingle GlaxoSmithKline Leyden Academy on Vitality and Dr Frans van der Ouderaa Ageing Professor Erika von Mutius Ludwig-Maximilian University Professor Robert Webb University of Nottingham Until Mar 2012 Professor Peter Weissberg British Heart Foundation Professor Christine Williams University of Reading Observers Changed title Dr Anne-Marie Coriat Medical Research Council Jan 2013 Biotechnology and Biological Sciences Dr Alf Game Until Jun 2013 Research Council Biotechnology and Biological Sciences Mr Brian Harris Joined Jul 2013 Research Council Panel Advisers – Assessment Phase 2014 Ms Katherine Branch University of Warwick Last updated: 21 January 2015 Panel A Dr Helen Reddy University of St Andrews Ms Gillian Rendle University of Oxford Last updated: 21 January 2015 Panel
    [Show full text]
  • AI Blasts Off
    JUNE 2021 # 76 Upfront In My View Business Sitting Down With Drug delivery: microneedles How digital tech can Plugging the cell and gene Maik Jornitz – inspiring the that melt away improve lab efficiency skills gap next generation 08 18 42 – 44 50 – 51 AI Blasts Off How supercomputers and algorithms will lead to a smart new era of drug development 22 – 31 www.themedicinemaker.com How Do You Balance Today’s Demands With Tomorrow’s Discoveries? Modify. Intensify. Amplify. Partner with Sartorius to know where, when and how to intensify key processes, increasing throughput up to four times, doubling productivity and achieving flexibility to meet the demands of today while preparing for the discoveries of tomorrow. Learn More About Process Intensification www.sartorius.com/process-intensification What Do We Do About Distribution? Editorial COVID-19 vaccine rollout is a lottery, with some countries faring much better than others ver 70 percent of people over the age of 18 have received a first dose of COVID-19 vaccine in the UK. And over 40 percent have received Otwo doses. But when it comes to my country’s progress, I can’t say I’m particularly proud. The UK has received a steady supply of vaccines ever since the first approvals. Meanwhile in some low- income countries, even frontline healthcare workers have not yet been vaccinated. And in other wealthy European countries, there are still substantial numbers of vulnerable people who are not vaccinated. I have four relatives (aged 63–75) living overseas in EU countries; two have received a first dose but were turned away from booked appointments to receive their second doses because of a lack of supply (one month later and still no sign).
    [Show full text]
  • Newsletter Available Here
    Issue 6 - February 2014 IN THIS ISSUE USEFUL LINKS Sixty Seconds with... Dr Nigel Rudgewick-Brown, MSD IT Services Find out more about what's happening across IT News the Division: Lab Talk - Professor Peter Rothwell, Stroke Prevention Research Unit Athena SWAN News In the News Board Business Current Seminars and Events Library News Past OxfordMedSci News issues Opportunities and Updates And Finally... Do you have news or events that you would like to promote? Or would you like your lab/centre/unit to feature in a future issue of Lab Talk? For further information, please contact [email protected] Copy deadline for next issue: 9:00am, Monday 3 March 2014 SIXTY SECONDS WITH ... IT NEWS Dr Nigel Rudgewick-Brown, Director of MSD IT Services In this issue, we launch a new section, IT News. Keep up to date with everything IT from the Medical Sciences Division, the University and beyond! In this issue, Dr Nigel Rudgewick-Brown, Director of MSD IT Services, reminisces on the days before the computing revolution, and Today's topics include: reminds us how important these little plastic The end of the line for Microsoft Windows XP boxes have become in our everyday lives! Information Security…? Tell us a little about your role The SecrIT (sorry) lives of freshers I run the MSD IT Services (formerly IMSU). We try WWW Domain Names - New policy in effect to support many MSD departments and units as efficiently as possible without compromising quality of service. I see my main role as getting the very best from every Read more..
    [Show full text]
  • Open Innovation in Drug Discovery and Development
    Wellcome Trust Frontiers Meeting Precompetitive Drug Boundaries: Open Innovation in Drug Discovery and Development Wellcome Trust, London 17–18 June 2010 Precompetitive Drug Boundaries: Open Innovation in Drug Discovery and Development 17–18 June 2010 Wellcome Trust, London OVERVIEW I. Background and aims On 17 and 18 June 2010, the Wellcome Trust convened 50 leaders from academia, technology transfer, the biotechnology and pharmaceutical sectors and other professional bodies to discuss open innovation strategies for drug discovery and development. At present, the cost of bringing new drugs to the commercial market is becoming increasingly unsustainable. Therefore, the market has been driven to develop alternative strategies for innovation, including partnerships with the biotechnology sector and academia and the outsourcing of chemistry, screening and lead-optimisation activities. There is some evidence that ‘open source’ science and public–private partnerships could energise the quest for new drugs. The Trust, in combination with a specifically constituted Scientific Steering Committee, developed this Frontiers Meeting to catalyse discussion on the specific challenges facing drug discovery and to suggest a framework by which the Trust can facilitate improvement. The aims of the meeting were to: • stimulate an open and inclusive discussion with stakeholders interested in the drug development process • identify bottlenecks in the drug development process where precompetitive approaches could add value • identify common ideas and alternative strategies for innovation that benefit all stakeholders • stimulate pharmaceutical industry and academic partnerships • stimulate collaborations for research • facilitate networking and business connections • develop ideas to influence government policy. II. Structure of the meeting Five discussion sessions were held over two days to address the key issues and lessons to be learnt within drug discovery and development.
    [Show full text]
  • BBSRC Annual Report and Accounts 2014-2015
    Biotechnology and Biological Sciences Research Council Annual Report and Accounts 2014 - 2015 Biotechnology and Biological Sciences Research Council (BBSRC) Annual Report and Accounts 2014 -2015 Presented to Parliament pursuant to Schedule 1, paragraphs 2 [2] and 3 [3] of the Science and Technology Act 1965. Ordered by the House of Commons to be printed 7th July 2015 HC 138 © Biotechnology and Biological Sciences Research Council (2015) The text of this document (this excludes, where present, the Royal Arms and all departmental or agency logos) may be reproduced free of charge in any format or medium provided that it is reproduced accurately and not in a misleading context. The material must be acknowledged as Biotechnology and Biological Sciences Research Council copyright and the document title specified. Where third party ma erial has been identified, permission rom the respective copyright holder must be sought. Any enquiries related to this publication should be sent to us at [email protected] This publication is available at https://www.gov.uk/government/publications Print ISBN 9781474118132 Web ISBN 9781474118149 Printed in the UK for the Williams Lea Group on behalf of the Controller of Her Majesty’s Stationery Office ID 28041502 07/15 Printed on paper containing 75% recycled fibre con ent minimum Contents STRATEGIC REPORT Chair’s statement 2 Chief Executive’s summary 3 Financial review 23 Key funding & performance data 25 Sustainability 30 DIRECTORS REPORT Corporate information 32 Remuneration report 34 ANNUAL ACCOUNTS 2014-2015 Governance Statement by the Chief Executive 40 Financial Statements for the year ended 31 March 2015 51 Acronyms 76 This Report provides an overview of BBSRC’s major activities during the period 1 April 2014 to 31 March 2015.
    [Show full text]
  • Annual Review 2017
    ANNUAL REVIEW 2017 TODAY’S SCIENCE TOMORROW’S MEDICINES CONTENTS ABOUT THE SOCIETY About the Society & mission statement 02 The British Pharmacological Message from our President (2016–2017) 03 Society leads the way in the and Chief Executive research and application Our year in numbers 04 of pharmacology around Promoting & advancing 05 the world. We are a friendly pharmacology and collaborative global Leading the way in the research & 10 application of pharmacology community, with around Nurturing our community 23 4,000 members from Sponsors & donors 33 more than 60 countries Financials 34 worldwide. Looking ahead: our 2018 objectives 36 Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers pharmacology in all its forms, including laboratory, clinical, and toxicological aspects. MISSION The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. Specifically, the Society is concerned with the discovery, mechanism of action, use and safety of drugs in humans and animals, in order to contribute to education and the understanding and relief of suffering. 02 Annual Review 2017 MESSAGE FROM OUR PRESIDENT (2016–2017) AND CHIEF EXECUTIVE 2017 was a year of growing ambition for the Society. It also marked the conclusion and review of one five-year strategy and the planning and launch, at the end of the year, of a new one. During this period of transition we remained focused on meeting the needs of our members, and on delivering our core mission: to promote and advance the whole spectrum of pharmacology.
    [Show full text]
  • Biotechnology and Biological Sciences Research Council Annual Report and Accounts 2009
    Published by TSO (The Stationery Office) and available from: Online www.tsoshop.co.uk Annual Report and Accounts Mail, Telephone Fax & E-Mail TSO PO Box 29, Norwich, NR3 1GN Telephone orders/General enquiries 0870 600 5522 Order through the Parliamentary Hotline Lo-Call 0845 7 023474 Fax orders: 0870 600 5533 E-mail: [email protected] Textphone: 0870 240 3701 The Parliamentary Bookshop 12 Bridge Street, Parliament Square, London SW1A 2JX Telephone orders/ General enquiries: 020 7219 3890 Fax orders: 020 7219 3866 Email: [email protected] Internet: http://www.bookshop.parliament.uk TSO@Blackwell and other Accredited Agents Customers can also order publications from TSO Ireland 16 Arthur Street, Belfast BT1 4GD Telephone orders/general enquiries: 028 9023 8451 Fax orders: 028 9023 5401 2009 - 2010 Biotechnology and Biological Sciences Research Council Annual Report and Accounts 2009 - 2010 Presented to Parliament pursuant to Schedule 1, sections 2 [2] and 3 [3] of the Science and Technology Act 1965. Ordered by the House of Commons to be printed 4 April 2011. HC585 LONDON: The Stationery Office £20.50 © Biotechnology and Biological Sciences Research Council (2011) The text of this document (this excludes, where present, the Royal Arms and all departmental and agency logos) may be reproduced free of charge in any format or medium providing that it is reproduced accurately and not in a misleading context The material must be acknowledged as Biotechnology and Biological Sciences Research Council copyright and the document title specified. Where third party material has been identified, permission from the respective copyright holder must be sought.
    [Show full text]
  • BBSRC Annual Report and Accounts 2008-2009
    PUBLIC HEALTH POLICY KNOWLEDGE SCIENTIFIC ADVANCEMENT EQUIPMENT PROCESSES INTERNATIONAL DEVELOPMENT PRODUCTS DELIVERING INWARD EXCELLENCE INVESTMENT WITH IMPACT NEW TRAINING COMPANIES PUBLIC ENGAGEMENT SKILLS Published by TSO (The Stationery Office) and available from: WEALTH CREATION Online www.tsoshop.co.uk SOCIETAL Mail, Telephone Fax & E-Mail ISSUES TSO KNOWLEDGE ECONOMY PO Box 29, Norwich, NR3 1GN Telephone orders/General enquiries 0870 600 5522 Order through the Parliamentary Hotline Lo-Call 0845 7 023474 JOBS Fax orders: 0870 600 5533 SCHOOLS E-mail: [email protected] Textphone: 0870 240 3701 The Parliamentary Bookshop COMMUNICATION 12 Bridge Street, Parliament Square, London SW1A 2JX Telephone orders/ General enquiries: 020 7219 3890 Fax orders: 020 7219 3866 Email: [email protected] Internet: http://www.bookshop.parliament.uk TSO@Blackwell and other Accredited Agents ANNUAL REPORT & ACCOUNTS 2008 - 2009 Customers can also order publications from TSO Ireland 16 Arthur Street, Belfast BT1 4GD 028 9023 8451 Fax 028 9023 5401 BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL ANNUAL REPORT & ACCOUNTS 2008 - 2009 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General, in pursuance of Schedule 1, sections 2 [2] and 3 [3] of the Science and Technology Act 1965. Ordered to be printed by the House of Commons 20 July 2009. HC587 LONDON: The Stationery office £19.15 Contents PART 1 MANAGEMENT COMMENTARYENTARY Chairman’s statement 1 Chief Executive’s report 2 Overview, policy development
    [Show full text]
  • Biotechnology and Biological Sciences Research Council Annual
    PUBLIC HEALTH POLICY KNOWLEDGE SCIENTIFIC ADVANCEMENT EQUIPMENT PROCESSES INTERNATIONAL DEVELOPMENT PRODUCTS DELIVERING INWARD EXCELLENCE INVESTMENT WITH IMPACT NEW TRAINING COMPANIES PUBLIC ENGAGEMENT SKILLS WEALTH CREATION SOCIETAL ISSUES KNOWLEDGE ECONOMY JOBS SCHOOLS COMMUNICATION ANNUAL REPORT & ACCOUNTS 2008 - 2009 BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL ANNUAL REPORT & ACCOUNTS 2008 - 2009 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General, in pursuance of Schedule 1, sections 2 [2] and 3 [3] of the Science and Technology Act 1965. Ordered to be printed by the House of Commons 20 July 2009. HC587 LONDON: The Stationery Office £19.15 © Crown Copyright 2009 The text in this document (excluding the Royal Arms and other departmental or agency logos) may be reproduced free of charge in any format or medium providing it is reproduced accurately and not used in a misleading context. The material must be acknowledged as Crown copyright and the title of the document specified. Where we have identified any third party copyright material you will need to obtain permission from the copyright holders concerned. For any other use of this material please write to Office of Public Sector Information, Information Policy Team, Kew, Richmond, Surrey TW9 4DU or e-mail: [email protected] ISBN 978-0-10-296063-1 Contents PART 1 MANAGEMENT COMMENTARY Chairman’s statement 1 Chief Executive’s report 2 Overview, policy development and strategic direction, supporting the research community Key funding
    [Show full text]
  • The Human Factor: Driving Digital Solutions for 21St Century Health
    THE HUMAN FACTOR DRIVING DIGITAL SOLUTIONS FOR 21ST CENTURY HEALTH AND CARE The Final Report of the National Centre for Universities and Business Task Force on Digital Health and Care The National Centre for Universities and Business Promoting business-university collaboration for a prosperous and inclusive economy and society The National Centre for Universities and Business (NCUB) is an independent and not-for- profit membership organisation that promotes, develops and supports university-business collaboration across the UK. Dedicated to Professor Patrick G Johnston, Former Vice-Chancellor, Queen’s University Belfast and original co-Chair of the Task Force, who died in June 2017. 3 Foreword The challenges and promises of digital health and care are a global preoccupation. To recommend more effective implementation and commercial success in the UK, the National Centre for Universities and Business assembled a Task Force of more than 50 experts from business, universities, research councils, consultancies, public and commercial health and social care providers, policy makers and patient groups. This team explored ways in which universities, industry, public and private health and care providers, government, patients and users can successfully partner to deliver the changes necessary for 21st century healthcare. In this, our final report, we focus on the human factors in bringing about transformational change through digital technology. We are grateful for all who shared their hard-won insights and vision, and commend the conclusions
    [Show full text]
  • EMBL-EBI Annual Scientific Report 2013
    EMBL-European Bioinformatics Institute Annual Scientific Report 2013 On the cover Structure 3fof in the Protein Data Bank, determined by Laponogov, I. et al. (2009) Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nature Structural & Molecular Biology 16, 667-669. © 2014 European Molecular Biology Laboratory This publication was produced by the External Relations team at the European Bioinformatics Institute (EMBL-EBI) A digital version of the brochure can be found at www.ebi.ac.uk/about/brochures For more information about EMBL-EBI please contact: [email protected] Contents Introduction & overview 3 Services 8 Genes, genomes and variation 8 Molecular atlas 12 Proteins and protein families 14 Molecular and cellular structures 18 Chemical biology 20 Molecular systems 22 Cross-domain tools and resources 24 Research 26 Support 32 ELIXIR 36 Facts and figures 38 Funding & resource allocation 38 Growth of core resources 40 Collaborations 42 Our staff in 2013 44 Scientific advisory committees 46 Major database collaborations 50 Publications 52 Organisation of EMBL-EBI leadership 61 2013 EMBL-EBI Annual Scientific Report 1 Foreword Welcome to EMBL-EBI’s 2013 Annual Scientific Report. Here we look back on our major achievements during the year, reflecting on the delivery of our world-class services, research, training, industry collaboration and European coordination of life-science data. The past year has been one full of exciting changes, both scientifically and organisationally. We unveiled a new website that helps users explore our resources more seamlessly, saw the publication of ground-breaking work in data storage and synthetic biology, joined the Global Alliance for Genomics and Health, built important new relationships with our partners in industry and celebrated the launch of ELIXIR.
    [Show full text]